NCT02548650View on ClinicalTrials.gov

Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

PHASE4CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

March 25, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

February 14, 2019

Conditions
Myocardial InfarctionDiabetes MellitusPeripheral Arterial Disease
Interventions
DRUG

Vorapaxar

Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days

DRUG

Clopidogrel

Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days

DRUG

Aspirin

Triple therapy with DAPT plus vorapaxar(vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days

Trial Locations (1)

32209

University of Florida, Jacksonville

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Florida

OTHER

NCT02548650 - Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus | Biotech Hunter | Biotech Hunter